StemCell Therapy

Trending Eyesight Test Equipment Market: Covid-19 Outbreak Impact Analysis

Toronto, Canada: The global Eyesight Test Equipment Market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. QY Researchs latest publication, titled global Eyesight Test Equipment market, offers an insightful take on the drivers and restraints present in the market. It assesses the historical data pertaining to the global Eyesight Test Equipment market and compares it to the current market trends to give the readers a detailed analysis of the trajectory of the market.

Top Key players cited in the report: EyeNetraBhavana MDCEssilor InternationalAlcon, Inc.HeineHeidelberg Engineering GmbHSeiko Optical Products Co., Ltd.Nidek Co., Ltd.Carl Zeiss AGHoya CorporationAbbott Medical Optics.Inc.Johnson & Johnson Vision Care.Inc.Shenzhen Certainn Technology

Get Free PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart)

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Eyesight Test Equipment Market which would mention How the Covid-19 is Affecting the Eyesight Test Equipment Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Eyesight Test Equipment Players to Combat Covid-19 Impact.

The research report covers the trends that are currently implemented by the major manufacturers in the Eyesight Test Equipment market including adoption of new technology, government investments on R&D, shifting in perspective towards sustainability, and others. Additionally, the researchers have also provided the figures necessary to understand the manufacturer and its contribution to both regional and global market:

The research report is broken down into chapters, which are introduced by the executive summary. Its the introductory part of the chapter, which includes details about global market figures, both historical and estimates. The executive summary also provides a brief about the segments and the reasons for the progress or decline during the forecast period. The insightful research report on the global Eyesight Test Equipment market includes Porters five forces analysis and SWOT analysis to understand the factors impacting consumer and supplier behavior.

Segmentation by Type:

PortableStationary

Segmentation by Application:

ChildrenAdultsThe Elder

The chapter on regional segmentation details the regional aspects of the global Eyesight Test Equipment market. It highlights the political scenario in the market and the anticipates its influence on the global Eyesight Test Equipment market.

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) North America (the United States, Mexico, and Canada.) South America (Brazil etc.) The Middle East and Africa (GCC Countries and Egypt.)

The report answers important questions that companies may have when operating in the global Eyesight Test Equipment market. Some of the questions are given below:

What will be the size of the global Eyesight Test Equipment market in 2025? What is the current CAGR of the global Eyesight Test Equipment market? Which product is expected to show the highest market growth? Which application is projected to gain a lions share of the global Eyesight Test Equipment market? Which region is foretold to create the most number of opportunities in the global Eyesight Test Equipment market? Will there be any changes in market competition during the forecast period? Which are the top players currently operating in the global Eyesight Test Equipment market? How will the market situation change in the coming years? What are the common business tactics adopted by players? What is the growth outlook of the global Eyesight Test Equipment market?

The scope of the Report:

The report segments the global Eyesight Test Equipment market on the basis of application, type, service, technology, and region. Each chapter under this segmentation allows readers to grasp the nitty-gritties of the market. A magnified look at the segment-based analysis is aimed at giving the readers a closer look at the opportunities and threats in the market. It also address political scenarios that are expected to impact the market in both small and big ways.The report on the global Eyesight Test Equipment market examines changing regulatory scenario to make accurate projections about potential investments. It also evaluates the risk for new entrants and the intensity of the competitive rivalry.

Grab Best Discount on Eyesight Test Equipment Market Research Report [Single User | Multi User | Corporate Users] @ https://www.supplydemandmarketresearch.com/home/contact/1201758?ref=Discount&toccode=SDMRLI1201758

Table of Contents

Report Overview: It includes six chapters, viz. research scope, major manufacturers covered, market segments by type, Eyesight Test Equipment market segments by application, study objectives, and years considered.

Global Growth Trends: This section has three chapters- Industry Trends, Growth Rate of Major Producers and Production Analysis.

Eyesight Test Equipment Market Share by Manufacturer: Here, production, revenue, and price analysis by the manufacturer are included along with other chapters such as expansion plans and merger and acquisition, Distribution of products, service areas and headquarters provided by major manufacturers.

Market Size by Type: This includes price analysis by type, production value market share, and production market share.

Market Size by Application: This section includes Eyesight Test Equipment market consumption analysis by application.

Profiles of Manufacturers: Here, leading players of the global Eyesight Test Equipment market are studied based on sales area, key products, gross margin, revenue, price, and production.

Eyesight Test Equipment Market Value Chain and Sales Channel Analysis: It includes customer, distributor, Eyesight Test Equipment market value chain, and sales channel analysis.

Market Forecast: Production aspects: In this part of the report, the author focused on predicting production and production value, forecasting the main producers, and predicting production and production value by production type.

About Us:We have a strong network of high powered and experienced global consultants who have about 10+ years of experience in the specific industry to deliver quality research and analysis. Having such an experienced network, our services not only cater to the client who wants the basic reference of market numbers and related high growth areas in the demand side, but also we provide detailed and granular information using which the client can definitely plan the strategies with respect to both supply and demand side.

Contact Us: Nimesh H302-20 Misssisauga, Valley, Missisauga,L5A 3S1, Toronto, Canada Phone Number: +1-276-477-5910Email- [emailprotected]

View post:
Current Trends: Eyesight Test Equipment Market 2020: What are the key opportunities? - Cole of Duty

There is little evidence to link Covid-19 to eyesight problems, the Royal College of Ophthalmologists and Moorfields Eye Hospital have said.

Downing Street aide Dominic Cummings said on Monday that he drove to Barnard Castle with his wife and child in order to test his eyesight before making the drive back home to London.

He was backed up by Prime Minister Boris Johnson, who suggested he too had suffered problems with his vision after contracting coronavirus.

Mr Johnson told the daily Downing Street briefing on Monday: Im finding I have to wear spectacles for the first time in years, I think because of the effects of this thing.

So Im inclined to think thats very, very plausible, that eyesight can be a problem associated with coronavirus.

Moorfields Eye Hospital said on Tuesday there was little evidence at the moment of a link and said more data was needed.

A statement said: At present, there is very little evidence to suggest that Covid-19 can affect eyesight.

Cases where Covid-19 is recorded alongside an impact on eyesight are rare, so we cannot establish a direct causal effect.

We need more data to be collected on Covid-19-related eye conditions to see if there is an association.

The Royal College of Ophthalmologists also said it was unable to report on the link due to a lack of evidence.

A statement said the College is unable to report on the association of vision impairment, as a result of a patient contracting Covid-19, due to a lack of evidence.

A direct causal effect can only be established through the reporting of proven cases of Covid-19 patients and their symptoms.

The College said its scientific journal, Eye, has recently published a collection of research papers looking at Covid-19 patients and eye health.

One of these papers points to potential problems experienced by some patients in intensive care, including corneal infection, inability to close the eyes and the eye surface becoming very dry.

The College said: We believe that there have been a few cases reported on viral conjunctivitis and a statement was issued on this topic, in association with the College of Optometrists, in March.

But Robert MacLaren, professor of ophthalmology at the University of Oxford, said coronavirus can affect the eyes in several ways.

It was reported in approximately one third of patients in Wuhan (China) in a recent study.

The ocular manifestations in the Wuhan patients included conjunctivitis, conjunctival hyperemia (red eye), chemosis (eye swelling), epiphora (watery eye) and increased secretions (sticky eye).

Any of the above symptoms may affect vision and affected patients would be advised to drive with caution or not at all if there was significant blurring of vision or double vision.

See the original post:
Coronavirus in Scotland RECAP: death toll reaches 2,291 as hospitalisations fall by 69 - Scotland on Sunday

LOS ANGELES--(BUSINESS WIRE)--MiraDx, a Los Angeles-based molecular genetics company that transitioned its CLIA-certified lab to provide COVID-19 tests for essential workers, is now expanding access to its PCR viral testing to public and private universities and colleges across the country. MiraDx aims to enable students, faculty, and staff to resume on-campus education later this year in an environment that provides a clear framework and easy and comprehensive access to highly accurate testing for the COVID-19 virus.

MiraDx is able to develop testing programs customized to the needs of an individual institution. Notably, the MiraDx lab, which is now exclusively processing COVID-19 tests, has dedicated reserved capacity for college programs, both to optimize turnaround time and mitigate the backlog many other labs are currently experiencing. With specific days allocated to individual schools, MiraDx will be able to deliver test results back to school officials through a secure server within 48 hours of receipt at the lab.

Accurate and sensitiveCOVID-19 testing of all Americans is of the utmost importance, said Dr. Joanne Weidhaas, co-founder of MiraDx. As our company continues to provide testing for thousands of first responders and essential workers, we have also turned our attention to another matter of national importance: enabling our youth to continue their on-campus education as safely and as soon as possible. Our goal is to contribute in a meaningful way to institutions of higher learning to allow students, faculty, and staff to return to campus in good health and give parents peace of mind that their children are safe.

MiraDxs discussions with over 100 schools across the country, along with guidance from health officials, have helped to inform the development of emerging testing protocols, to include day one clearance testing of the entire student body and faculty, followed by repeat sentinel testing throughout the semester.

We are focused on delivering the highest quality, most sensitive and dependable testing programs possible, said Dr. Weidhaas, herself an educator at UCLA. We are only going to commit to programs today we know we can achieve in the fall we are not going to sell capacity we do not have, and in fact, we are building in a buffer of capacity in each college testing day.

MiraDx has a CLIA-certified lab with a high complexity molecular processing designation that allows it to conduct PCR testing, a highly sensitive approach that results in over 90 percent accuracy in COVID-19 testing and is considered the gold standard in testing. To determine whether an individual is infected with COVID-19, a sample is collected from a swab of the back of the throat, where the highest viral load exists for this coronavirus. The MiraDx test includes an air-tight vial, collection swab, a biohazard bag, and simple instructions for collecting the sample, which is collected under the supervision of a healthcare professional. MiraDxs analysis technique can identify as little as four copies of COVID-19 RNA in an individual sample, meaning that the virus can be detected even during the early stages of infection and/or in asymptomatic individuals. Non-PCR based testing approaches are either less sensitive (resulting in more false negatives) or do not tell patients when they are no longer contagious, which either leaves them in quarantine too long or presents the risk of them coming out of quarantine too soon.

MiraDxs COVID-19 test has been developed in line with the FDAs Emergency Use Authorization requirements.

About MiraDx

Dr. Joanne Weidhaas, MD, PhD, MSM is the co-founder of MiraDx and a professor and vice-chair in the department of radiation oncology at UCLA.

MiraDx is a Los Angeles-based molecular genetics company that identifies, validates, develops, and delivers novel germline biomarker tests for individualized cancer treatment, and now performs COVID-19 testing. Its goal is to improve human health and advance personalized medicine through the application of novel functional germline biomarkers. To learn more about MiraDx, please visit miradx.com. Please send inquiries to info@miradx.com

Read the original here:
Molecular Genetics Company MiraDx Offers COVID-19 Viral Testing To U.S. Universities and Colleges - Business Wire

TribLIVE's Daily and Weekly email newsletters deliver the news you want and information you need, right to your inbox.

Fears about catching coronavirus from contaminated surfaces have driven some people to become compulsive about cleaning countertops and wiping down their groceries. As the pandemic took hold, some poison centers even reported increased calls about excessive exposure to cleaning agents.

In recent weeks, the Centers for Disease Control and Prevention appeared to adjust its stance on surface transmission of the coronavirus. New language on its website was interpreted as deemphasizing concerns, creating some confusion about the risk of catching covid-19 from frequently touched objects.

Pittsburgh-based infectious disease and critical care physician Dr. Amesh Adalja said that while the contact spread of the virus can certainly occur, it is not responsible for the bulk of transmission.

Weve always known that there is a small contribution from contaminated surfaces. I think the CDC guidance reflects the fact that were trying to focus on the main route of how this virus gets from person to person. It is from another person directly, Adalja said. Our public health strategy needs to be focused on eliminating the person-to-person spread,and there can be less emphasis on contact spread.

After some news outlets ran with the idea that the CDC was no longer concerned about surface transmission, the agency issued a statement clarifying that contact with a contaminated surface is still one way to catch covid-19.

It may be possible that a person can get covid-19 by touching a surface or object that has the virus on it and then touching their own mouth, nose or possibly their eyes. But this isnt thought to be the main way the virus spreads, the statement said. The change on the website was intended to make it easier to read, and was not a result of any new science.

Dr. Arvind Venkat, an Allegheny Health Network emergency physician, observed that we live in a hyper-connected world, and social media can create controversies that arent always there. So, the combination of not having consistent communication and an environment in which everything is so fragmented is a bad combination in a public health crisis.

Venkat also past president of the Pennsylvania College of Emergency Physicians said public health authorities must communicate carefully and accurately to maintain trust with the public.

Since this is a new virus, were still learning as we go along. The fact that there is contradictory and changing data is to be expected, Venkat said. So, when something changes, we need to make sure that we convey that in a systematic way so that it doesnt get perceived as going back and forth.

So, what are the chances of catching covid-19 from an object or surface laden with germs?

I think the relative risk of picking it up from common things given the precautions that everybody is taking is much lower, said Seema Lakdawala, assistant professor of microbiology and molecular genetics at the University of Pittsburgh School of Medicine.

But if you are a health care worker and you are working in a hospital setting with patients that are symptomatic and coughing and sneezing large volumes of the virus into their environment then, yes, the risk of catching it from a surface is much higher.

The feeling among medical experts who spoke with the Tribune-Review is people are unlikely to catch the virus from doing things like grocery shopping. Lakdawala, an expert in virus transmission, said she does not wipe down her groceries.

Everyone has their own comfort level. If somebody is taking the time to wipe down every single material three times, I would say that is a waste of their time, Lakdawala said. I think its important for the general public to understand, What kind of information do I need to make a risk assessment for myself?

Adalja said that while its important for people to continue to take protective action, they can be a little less concerned about contaminated surfaces they may have touched.

I think people can be less worried about making sure they scrub their groceries. Thats less likely to be impactful than other things, like washing your hands and trying to avoid crowded spaces and other social-distancing measures.

Paul Guggenheimer is a Tribune-Review staff writer. You can contact Paul at 724-226-7706 or pguggenheimer@triblive.com.

Categories:Coronavirus | Editor's Picks | Health | Local | Allegheny | Top Stories

TribLIVE's Daily and Weekly email newsletters deliver the news you want and information you need, right to your inbox.

Read this article:
Western Pa. experts weigh chances of catching coronavirus from contaminated objects - TribLIVE

AP Photo/Crime Stoppers via Houston Chronicle, File

The case almost went cold for good.

On Jan. 15, 2012, Gelareh Bagherzadeh was sitting in the driver's seat of her silver Nissan Altima when she was shot twice in the head, point blank, from the passenger side of her car. She had been talking to a friend, who heard her scream, then silence, and called 911. Gelareh's cell phone was found at her feet. The car had smashed into the garage of a townhouse, one in a row behind The Galleria, an upscale mall in Houston, and the acrid smell of burnt tire rubber was thick in the air.

Her purse and wallet were there, seemingly intact, so it didn't appear to be a robbery. There were no signs of sexual assault.

It was a mystery, one thathad enough twists and turnsto end up the subject ofDateline and NBC News' latest true crime podcast, Motive for Murder.

"I'm no stranger to mystery, to secrets people are desperately trying to hide, and the things those people are willing to do to get what they want," Motive for Murderhost and longtimeDateline correspondent Josh Mankiewiczexplained as episode one got underway.

**This is documented real life, and Dateline covered the case in 2019,sothis isn't exactly a SPOILERalert, but there are major revelations about the case ahead.

An early theory that turned the story into national news was that perhaps Gelareh's outspoken political views had gotten her killed. Perhaps the Iranian government was involved.

The 30-year-old had moved to Houston from her native Iran for school and was studying molecular genetics at the University of Texas MD Anderson Cancer Center when she was killed. But she remained plugged in to the troubles at home andshe took part in protests in Houston supporting theIranian Green Movement, which disputed the legitimacyof then-President Mahmoud Ahmadinejad's re-election in 2009 and was demanding regime change.

Her activism certainly worried her parents, Ebrahim Bagherzadeh and Monireh Zangeneh, but they remembered their daughter being unafraid of any potential consequencesthough, according to the Houston Chronicle, she had asked that her name not be used when the paper posted a video from a 2010 protest on its website.

Friends in Gelareh's inner circle were skeptical, however, that the Iranian government would "waste their energy and time" by orchestrating the death of a student activist all the way in Texas. Though "if they had...they would take credit for it" to warn off other dissidents, observed Gelareh's close friend, Kathy Soltis.

Local police said early on that they didn't suspect either apoliticalmotive or that she was targeted because of her ethnicity.

Fingerprints found on the car, the bullets recovered at the scene, a cigarette butt on the ground outside the car doorall were sent to the lab for forensic testing.

Dead ends, the lot.

In the meantime, detectives started probing the possibility that the motive had something to do with one of three overarching motives for so many murders: love, money or pride.

Houston PD homicide investigator DetectiveRichard Bolton, now retired, recalled to Mankiewicz the inevitable part of the probe when they looked into the men in Gelareh's life, including her fairly new boyfriend, Cory Beavers, and the friend who said he heard a scream on the phone seemingly seconds before she was shot,Robeen Bandarwho also was her ex-boyfriend.

Bandar explained (to police and Mankiewicz) thatthey had had an amicable breakup and had mutually decided they would be better off just being friends.

Police asked why heheard a scream but didn't recallhearinga gun shot or screeching tires. Bandar said it was probably shock or denial of what he may indeed have heard.

Onto Gelareh's current boyfriend, Cory, the last known person to see her alive.

He told police that she had surprised him by showing up at his house, but he had a test to study for so they only hung out for awhile. When sheleft, he told her to text him when she got home to let him know she had arrived safely. He never heard from or saw her again.

Cory said he didn't know Gelareh was dead until he drove up to her house the next day and a reporter approached him and asked if he knew anything about "the girl who lived here."

He knocked on the door and Ibrahim answered, and he was the one to tell Cory that Gelareh was dead.

Police also looked intocrimes with similar M.O.s in the area, wondering if she was the victim of a carjacking gone wrong. They looked at a lawsuit her father was embroiled in at the time with a former employer.

More dead ends.

Four months after the murder, police announced that the family was offering a $200,000 reward for information that led to justice for Gelareh, the largest Crime Stoppers reward on offer in the country at the time.

The dozen or so tips that merited follow-up also led nowhere. But then there was another shooting that November.

The victim was Cory Beavers' identical twin brother, Coty. And homicide detectives don't put much stock in coincidences.

Coty Beavers' wife, Nesreen Irsan,had called 911 to report that her boyfriend had been shot. "Why did God do this to me?"she's heard wailing on the call.

She had found her husband's body in their apartment when she returned home from work. She told police she last saw Coty that morning, when he walked her down to her car to see her off, as he usually did. When police responded to her 911 call, it was apparent he had been dead for awhile. It was later determined that his wedding ring had been moved from his ring finger to the middle finger of his left hand.

Coty and Nesreen were newlyweds. According to Cory, Nesreenalso a student at MD Anderson, like Cory and Gelarehwas originally interested in him, but Cory was determined to keep his mind on his studies and introduced Nesreen to Coty. Nesreen was friends withGelareh, meanwhile, and she's the one who introduced her to Cory after he saw the two of them walking together at school. He was smitten immediatelyand after talkingto her more at a party not long after, they started dating.

By the time his newlywed brother was killed, Corystill reeling from the murder of his girlfriendwas fed up with what he felt was time wasted by the police looking at him as a suspect and any other activity that didn't get them any closer to finding Gelareh's killer.

Nesreen, meanwhile, had her own traumatic past. In the summer of 2011 she had run away from her strict Muslim household and her controlling father, whom she described as "violent and abusive," with only the clothes she was wearing. She climbed out of a window and went to a neighbor's house and asked for a rideto Coty and Cory's mom Shirley Beavers' house in Spring, Texas.

Nesreen had been dating Coty and keeping it a secret from her father, Ali Irsan, with the help of her sister Nadiawho would simultaneously cover for Nesreen but also threaten to tell on her.

When Ali Irsan found out about Nesreen and Coty, he barred his 23-year-old daughter from leaving the house.

Mayra Beltran/Houston Chronicle via AP

Police had no recourse to bring Ali's adult daughter back to their house if she didn't want to be there, so Ali showed up at Shirley's house himself (how he found out where they lived,whether the address was online or Nadia told him, or whatever, they didn't know). Ali knocked on their neighbors' doors, offering $100 for information on Coty's whereabouts. In the ensuing days, the Beavers would go outside in the morning to find that the air had been let out of their tires, so they had to start moving their cars. An order of protection Nesreen obtained against her father didn't stop himbut that at least paved the way for police to obtain a warrant to search the Irsan family's home, as well as two other properties Ali owned. They found a dismantled hand gun.

Cory recalled to Mankiewicz a fight he witnessed between Nadia and Nesreen during college, ostensibly over a petty issue,in which Nadia told her sister, "'I can't wait until my dad puts a bullet in your head.'"

"I believed her," Cory said.

Melissa Phillip/Houston Chronicle via AP, File

Going through boxes of documents they'd confiscated, police found paperwork that indicated Ali Irsan was committing multiple acts of fraud, such as falsely claiming disability benefits and opening credit cards in his kids' names.

Sothe Harris County Sheriff's Department brought in theFBI, and ultimately a task force thatcame to includethe Montgomery and Harris County sheriff offices, the FBI, the Houston Police Department, the Social Security Administration Office and Homeland Security got to work.

According to authorities, Irsan, a naturalized citizen, had first come to the U.S. from Jordan in 1978 and proceeded to marry a blind woman whom he physically and sexually abused, and had four children with. While still married, he brought a teenage bride, Shmou, over from Jordan, and they had eight more children, including Nesreen and Nadia.

In 2014, Irsan was chargedin federal court with conspiracy to defraud the United States, theft of public money and benefits fraud, and Shmou and Nadia were arrested, too. In April 2015, he pleaded guiltyto conspiracy to defraud and was sentenced to 45 months in prison; his wife and daughterwere convicted of providing false statements as part of the fraud schemeand were each sentenced to two years in prison.

But back to the double murder investigation.

Yet another thing discovered in the course of the investigation into Irsan was the revelation that he had been pulled over by a Texas State Trooper on the day of Gelareh's murder. His wife and one of his sons were also in the cara silver Toyota Camry.

Which, incidentally, matched the description given by a witness back in 2012 who told police she saw what looked to be a silver Camry speeding away from the site of the shooting. Nothing had ever come of it.

The location and timing of the traffic stop put Irsan's car exactly where it would have been had he driven away from the crime scene after the shooting. Dash-cam footage showed Ali barely able to stand, and he told the trooper hewas diabetic and suffering from low blood sugar, so he had been speeding on his way to find sugar.

There was no evidence that he was a diabetic.

It was almost a fluke that the trooper still had the dash-cam footage after two years. According to Mankiewiecz, the officer just had a funny feeling about the guy...

Furthermore, per authorities and Cory Beavers, it turned out that Gelareh and Alihad crossed pathstheir seeming lack of interaction having been a nagging issue when trying to connect Ali to both her murder and that of his son-in-law.

AfterNesreen fled her family's home in 2011, Ali started calling her classmates under the guise of simply being a concerned dad.

Gelareh wasn't having it, and told him she saw right through what he was trying to do.

Toward the end of the year, he called again. Gelareh called back and first talked to Nadia, who then passed the phone to her father, who asked (according to Cory), "Is this that Iranian bitch?" Gelareh proceeded to tell him off in Farsi. He hung up. A few weeks later she was dead.

In May 2014, Ali Irsan was charged with Gelareh's murder. That charge would be dropped for tactical reasons, because once authorities had connected him to both killings, Irsan was charged in 2015 with capital murder, for what has since been characterized as two so-called "honor killings."

Or make that three. In 1999, Irsan fatally shot his 29-year-old son-in-law Amjad Alidam. He told police Alidam had been abusing his daughter, and he killed him in self-defense. Authorities later said they couldn't build a case to prove otherwise.

In 2018, jurors spent 35 minutes deliberating before convicting him of themurders of Gelareh Bagherzadeh and Coty Beavers.

During the penalty phase of the trial, a former neighborsaidthat Ali Irsan hadbragged to him that he "got away with murder" inthe death of his other son-in-law."He said he invited his son-in-law to his house and shot him," the witness, Randy Wilkinson, testified. "He said he shot him with a 12-gauge shotgun and planted a gun on him."

His sonNasim Irsan, the one who was in the Camry with him, pleaded guilty in both murders as well and was sentenced last August to 40 years in prison. Ali Irsan iscurrently on death row in Texas.

The finale ofMotive for Murderwill be outThursday, June 4, wherever you get your podcasts.

(E! and NBC News are both members of the NBCUniversal family.)

Link:
All About the Twisted Story Behind Motive for Murder - E! NEWS

Growing up in Livermore, California, Janelle Ayres kept all kinds of petsrabbits, birds, fish, turtles, and her two favorites, Smokey the Siberian husky and Roman the German shepherd. She dreamed of becoming a veterinarian, but learning about genetics in high school led her to study molecular and cell biology at the University of California (UC), Berkeley. She then had to choose among vet school, med school, and a PhD program. Attending a talk by Stanley Falkow, whom she calls the godfather of microbial pathogenesis, helped her decide to pursue microbiology. I loved the idea of host-microbe interactions, Ayres tells The Scientist, and that pathogens could be having such dramatic effects on the hosts biology.

After graduating in 2002, Ayres moved to Stanford to work with microbiologist David Schneider. He encouraged her to follow her own ideas, and after many hours spent PubMed wandering, she kept circling back to the same question: What does it mean to survive an infection? The dogma then was that surviving an infection required killing a pathogen, and while thats true in many cases, Ayres says, it didnt account for all infections.

Wheat, for example, can tolerate certain pathogens without treatment, leaving Ayres to wonder: if plants could endure infections, did animals also have this disease tolerance? To investigate, she injected fruit flies with Listeria. All of the flies, whether they died or not, had similar levels of bacteria, indicating that pathogen load or an inability to eradicate the infection wasnt what killed the insects. Ayres next analyzed the genetics of the flies and found tweaks in genes unrelated to the immune system that promoted tolerance of the infection. Animals, like plants, do tolerate disease, she showed.

Working on that project, Ayres was really engaged and thoughtful in a way that I now understand isnt very typical of graduate students, Schneider says. She finished her PhD in 2009 and returned to UC Berkeley for a postdoc in the lab of microbiologist and immunologist Russell Vance. Four years later, she opened her own lab at the Salk Institute for Biological Studies in La Jolla, California.

There, Ayres set out to investigate whether disease tolerance existed in mammals. She worked with mice, which tend to lose muscle mass after infection with Salmonella or Burkholderia thailandensis. And, just as in her earlier fruit fly experiment, she found that some mice experienced muscle wasting while others of the same strain didnt, even when the animals had similar pathogen levels. It turned out that a particular strain of E. coli in the microbiomes of surviving mice had helped them tolerate infection. Giving that E. coli strain to infected mice as a probiotic protected them against muscle wasting (Science, 350:55863, 2015).

Janelles work is remarkably creative in identifying mechanisms of tolerance and really digging deep and trying to understand how the mammalian host . . . can actually withstand typical bacterial infections, says Dan Littman, an immunologist at New York University who has tracked Ayress work. She has the ability to really think around problems without being held back by the conventional wisdom in the field.

In a 2017 Cellpaper, Ayres and her colleagues showed that when Salmonella typhimurium infects a mouse, the bacterium uses an effector protein called SlrP to manipulate the animals gut-brain axis. The mouse continues eating as a result, whereas with other infections the animal would lose its appetite. This manipulation of the animals behavior promotes host health and survival, along with pathogen transmission, Ayres says.

In a more recent experiment, she and her team analyzed gene activation in genetically identical mice infected with Citrobacter. Mice that survived had increased expression of genes regulated by iron. When her team fed iron-enriched chow to a new group of infected mice, 100 percent of the animals survived, despite the pathogens persistent presence in their organs.

Every experiment seems to surprise us, Ayres says, and were committed to pushing this field forward. The goal is translating the work into humans. When a patient is infected with a particular pathogen, she explains, I want to be able to define how I can intervene and shift them back onto a trajectory to a healthy state.

See the article here:
Janelle Ayres Explores the Ways in Which Animals Tolerate Disease - The Scientist

NEW YORK Employing tumor-normal sequencing, researchers have demonstrated that a significant number of advanced cancer patients learned germline findings that informed the treatment they received.

In one study, involving 12,000 patients treated at Memorial Sloan Kettering Cancer Center, researchers identified nearly 600 patients with recurrent or metastatic cancer who had actionable germline mutations, and 44 percent of them received targeted drugs either as part of the standard of care or as part of a research protocol.

Presenting the findings at the American Society of Clinical Oncology's virtual annual meeting, MSK's Zsofia Stadler said her group's study represents the most comprehensive assessment of the clinical utility of germline variants for guiding targeted therapy decisions in advanced cancer patients. This study, she said, demonstrates the "the importance of germline analysis for cancer treatment."

In another study, presented at the same meeting, researchers from the University of Michigan investigated the prevalence of actionable germline mutations in a cohort of around 1,000 patients, and found that 49 patients, or close to 5 percent, had therapeutically targetable germline mutations.

The findings from these two studies are timely given that cancer patients are increasingly having their tumors sequenced in the hopes of identifying precision therapy options. Studies have shown that after tumor profiling, approximately 10 percent of patients received results based on which they can receive precision drugs. Patients' tumors are often profiled using next-generation sequencing (NGS) panels that gauge hundreds of genes and also pick up clinically significant germline mutations, but often these findings are censored and not reported back to or discussed with the patient. This is likely because there is a perception that germline genetic mutations, which have been historically important for inherited cancer risk assessment, don't really impact the immediate care of patients.

"We know the identification of germline alterations has important implications for our cancer patients, including implementation of appropriate cancer surveillance measures, potential risk-reducing measures, and of course predictive genetic testing for at-risk relatives," said Stadler. "However, less is known about the clinical impact of germline findings on targeted cancer treatment."

At MSK, cancer patients can have their tumors profiled with the MSK-IMPACT NGS panel which gauges more than 400 genes. The goal of this testing, Stadler said, is to identify genetic mutations in the tumor that can be targeted with treatments. To do this, the cancer center sequences a patient's tumor tissue and normal blood sample, compares the detected mutations, and subtracts out the germline variants that occur in every cell in the body, not just the tumor. At the end of this process, only the somatic mutations found in the tumor are reported.

Starting in 2015, patients at MSK who received testing with MSK-IMPACT could provide consent under an institutional review board-approved protocol to receive separate germline testing for 88 genes associated with increased cancer risk. Between 2015 and 2019, nearly 12,000 patients agreed to this additional testing to learn if they harbored likely pathogenic or pathogenic mutations in any of these genes. If patients had pathogenic findings, this was noted in their medical record, which investigators then reviewed to assess whether the mutations could inform treatment.

Around half of these 12,000 tested patients had breast, prostate, pancreatic, or colorectal cancers, while the rest of the patients had a variety of rarer tumor types. Approximately 2,000 patients, or 17 percent, had likely pathogenic or pathogenic mutations, 682 of whom had mutations in high- or moderate-penetrance genes.

In terms of therapeutic actionability, Stadler and colleagues identified targetable mutations in 849 patients, or 7 percent. Since PARP inhibitors now can be given to patients with BRCA1 or BRCA2 mutations with certain types of cancers, mutations in these genes comprised more than half of the actionable findings. Nearly 20 percent of mutations were in Lynch syndrome genes, which can guide immunotherapy use.

MSK classifies the actionability of somatic variants detected by MSK-IMPACT using a three-tier system that emerged in the process of garnering FDA authorization for the panel. In authorizing that test, the FDA released a three-tier framework to help labs determine what information they could accurately communicate in test reports based on the evidence underlying detected biomarkers. The same system can also help oncologists prioritize which findings are most informative for their patient's care from the long list of genetic mutations often identified by these tests.

In the FDA's framework, tier 1 biomarkers are those that the agency has given companion diagnostic status based on evidence showing that they can determine which patients will or will not respond to a drug. Tier 2 biomarkers are "cancer mutations with evidence of clinical significance" that doctors can use in the care of cancer patients in line with guidelines and other information. Tier 3 biomarkers are "cancer mutations with potential clinical significance," which can help direct patients to clinical trials.

Since germline variations don't have a widely accepted system of classification for therapeutic actionability, Stadler and colleagues adapted this three-tier system for somatic variants to weigh the evidence on the 88 cancer risk genes. While 849 patients, or 7 percent, had targetable germline mutations in tier 1 and 2 genes, using all three tiers, around 1,000 patients, or nearly 9 percent, had germline mutations with therapeutic significance.

The researchers used the more stringent criteria germline mutations in tier 1 and 2 genes to try to guide treatment decisions for nearly 600 patients with recurrent or metastatic cancer. Ultimately, 44 percent received targeted drugs either as part of the standard of care or as part of a research protocol. Patients who received treatment had germline mutations in a variety of genes, though alterations in BRCA1 and BRCA2 drove a lot of the therapeutic decisions in the study.

As such, researchers explored this subset of patients in more detail. Of the 175 patients with BRCA1/2 germline mutations, 57 percent were classified as tier 1 mutations because patients had breast or ovarian cancer and were able to receive PARP inhibitors that had been FDA approved for their molecularly defined indication. More than 40 percent including 21 percent of pancreatic cancer patients and 11 percent of prostate cancer patients received PARP inhibitors under a research protocol. Since this study, however, the FDA has approved PARP inhibitors for BRCA-mutated pancreatic and prostate cancer.

"With the emergence of novel targeted treatments with new FDA indications, the therapeutic actionability of germline variants is likely to increase over time," Stadler said.

Germline testing for all advanced cancer patients?

The study led by Erin Cobain from the University of Michigan similarly demonstrated the clinical utility of germline findings from tumor testing, though on a smaller scale. The researchers conducted targeted exome sequencing for 1,700 genes and transcriptome sequencing on tumor and normal samples from approximately 1,000 patients with advanced solid tumors. Pathogenic germline variants were identified in 160 patients, or 16 percent. Of the deleterious cancer risk mutations identified during this process, 92 percent were not known before patients were tested as part of this protocol, "which indicates that current clinical criteria may not identify all patients at risk for cancer predisposition," Cobain said.

Close to 5 percent of patients had biomarkers that could inform their treatment, such as defects in DNA repair genes, which can be treated with PARP inhibitors, and mutations in mismatch repair gene defects that can be used to prescribe immunotherapy. Significant proportions of patients with rare tumors had pathogenic variants, such as 20 percent of sarcomas, 17 percent of hepatobiliary cancers, and 16 percent of cancers of unknown primary. Cobain highlighted that some of these patients with these rare tumors had germline mutations that could potentially be therapeutically targeted, which is important given the limited treatment options in these settings.

Ultimately, 11 patients received PARP inhibitors and immunotherapies based on germline findings. Two patients had a complete response, one had a partial response, and five had stable disease. Of the three patients who had progressive disease, two were breast cancer patients with germline ATM mutations treated with PARP inhibitors, and the third was a pancreatic cancer patient with a BRCA1 mutation who received a PARP inhibitor.

The results of this study "support consideration of directed germline testing in all patients with metastatic solid tumors to identify defects in DNA repair with therapeutic targets," Cobain said.

Needs infrastructure

To Funda Meric-Bernstam from MD Anderson Cancer Center, both of these studies demonstrate that if cancer centers are doing tumor/normal sequencing and looking for germline variants of clinical significance, they may not have to look too hard. However, she clarified that its also not "easy" to identify and report germline variants in this context. "This requires a lab to both analyze the normal [samples] and call pathogenic and likely pathogenic variants," she said.

Currently, there isn't a standardized method among tumor sequencing labs when it comes to dealing with germline findings. Some labs conduct only tumor testing, others conduct tumor-normal analysis but subtract germline findings, and still others perform tumor-normal testing and report only a subset of germline findings. Even if a lab sequencing only tumor tissue, tests will identify mutations in genes that are more likely to have occurred in the germline.

Meric-Bernstam noted that although the studies at MSK and the University of Michigan were done under IRB-approved protocols, in the real world when tumor sequencing is done, most patients aren't asked if they want to learn germline findings. "You really need infrastructure to return [results], to counsel, and to offer cascade testing," she said. "You need to facilitate the analysis of normal [samples] so you can ensure findings can be acted upon in a timely fashion, especially in patients with advanced disease. You need to have infrastructure in place for treatment matching and treatments available."

Though there are technical and infrastructural challenges to reporting out germline findings in the context of cancer tumor sequencing, genetics experts are increasingly of the opinion that it is no longer ethical to mask these findings, particularly given their increasingly important role in therapy selection as demonstrated by the ASCO studies. The American College of Medical Genetics and Genomics last month published a set of points that clinicians and genomics labs should consider when presumed germline variants are flagged during tumor sequencing.

Recognizing the varying practices in the field in this regard, the ACMG in its publication told genetic testing labs to be transparent about their ability to detect germline variants from tumor testing, as well as their reporting practices. Additionally, the ACMG told clinicians to take the opportunity when ordering tumor testing to evaluate the patient for clinical signs of an underlying hereditary cancer syndrome that may require germline testing.

According to Douglas Stewart, who is lead author of the ACMG paper and is a senior investigator within the National Cancer Institutes' Division of Cancer Epidemiology and Genetics, Clinical Genetics Branch, the aim of the association is to promote best practices. But it is also the association's hope, he recently said in an interview, that the issues laid out in the paper will start a discussion in the field about how "to capitalize on this huge opportunity of identifying germline variation in tumor sequencing so that it benefits as many people as possible."

Excerpt from:
Germline Results From Tumor-Normal Sequencing Guides Precision Therapy in Advanced Cancer Patients - Precision Oncology News

Cheetahs are majestic cats found in parts of Asia and Africa. Centuries ago, these magnificent runners roamed the Indian subcontinent, before they were forced into extinction by humans. They were hunted, kept captive and used by the Maharajas for hunting other animals, and by the mid-twentieth century, they became locally extinct. Today, in parts of Africa and Asia where these cats are found, the destruction of their habitatgrasslandsare threatening the surviving populations of wild cheetahs. In Iran, for example, the wild population of Asiatic cheetahs are struggling.

In a bid to reintroduce cheetahs in India, suggestions were made to bring in African cheetahs from Namibia to Indian forests. After a prolonged legal battle, in January 2020, the Supreme Court allowed the reintroduction of these foreign cheetahs. This move is thought to bolster conservation and tourism. But such decisions cannot be based on the rule of the land alone. One needs to have sufficient information and understanding of several aspects, including the evolution and genetics of cheetahs in a region, to succeed in such efforts.

Previous studies have shown that the now-extinct Indian cheetah was an Asiatic subspecies. However, we do not know how closely the Asiatic and African cheetahs are related. Now, a study published in the journal Scientific Reports has probed the evolutionary relationship between cheetahs. The study, consisting of a team of international researchers, included those from the Centre for Cellular & Molecular Biology (CCMB) Hyderabad, the Birbal Sahni Institute of Palaeosciences, Lucknow, and the Zoological Survey of India (ZSI), Kolkata.

The researchers started by sequencing the mitochondrial DNA fragments, present outside the nucleus of a cell in an organelle called mitochondria, of an Indian cheetah and two African cheetahs. The African cheetah samples came from Southeast Africa and Northeasteast Africa, which were imported to India at different times. These three sequences were then compared against 118 published cheetah mitochondrial DNA sequences from various regions of Africa and Asia.

Based on previous studies, it was believed that the Asiatic subspecies of cheetahs diverged from the African subspecies only 5000 years ago. However, the genetic analysis of the current study found that this divergence is older than thought, and may have happened about 72,200 years ago. As a result, the populations today are genetically very different from each other, say the researchers, explaining the genetic uniqueness of Asiatic cheetahs. The study also found that the Asiatic cheetah and the Southeast African are more closely related to one another than to Northeast African cheetah.

The current study also sheds some insights into the origin of all cheetahs using the genetic analysis. It suggests that the common ancestor of all cheetahs is approximately 1,38,900 years olda number that is twice the previous estimate of 67,000 years.

The findings not only inform us about the evolutionary history of the cheetahs but also provides grounds on making an informed choice for their conservation. Phylogenetics, the study of evolutionary relationships, shows the differences in the genetic traits and characters and evolutionary history among species. The unique genetic makeup seen in these subspecies of cheetah not only help differentiate the populations from each other but also help determine their capacity to adapt to changing conditions.

In India, the results of the study have implications on what subspecies of cheetahs should be reintroduced. Some argue that reintroducing cheetahs could be a misplaced priority right now since Indias lions and tigers are in greater peril. Others opine that with the reintroduction, the countrys grasslands may be saved. The debate is still wide open, and science may soon help resolve it.

More here:
New insights on the evolution of cheetahs may help decide the best move on reintroduction - Research Matters

Point of Care Molecular Diagnostic Device Market was valued at USD635.5 million in 2018 and is estimated to grow at a CAGR of XX% from 2018 to 2026.Point of Care Molecular Diagnostics Device Market, By RegionA point-of-care (POC) test is performed at or near the site where a patient initially encounters the health care system. It has a rapid turnaround time (approximately 15 min) and provides actionable information that can lead to better patient management.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/10995/

Some of the key market drivers include the increasing technological advancements, ability to diagnose infectious diseases at sites with a limited infrastructure, availability of clinical evidence for the safety and efficacy procedures, patients awareness about better healthcare options and readiness for rising healthcare expenditures, changing technology and innovation, changing demographics and lifestyles leading to an increased prevalence of peripheral vascular diseases, adoption of new products, rising demand for advanced medical instruments, geriatric population.

Point of Care Molecular Diagnostics Device Market is segmented by product & service, technology, application, end user, and region. Point of Care Molecular Diagnostics Device Market has the largest usage in Physician Offices, Hospital Emergency Departments & Intensive Care Units, and Research Institutes

Geographically, global point of care molecular diagnostics device market is classified into North America, Europe, Asia Pacific (APAC), and the Rest of the World (RoW). In 2018, North America is anticipated to have the largest share in the global adhesion barrier market. The largest ratio of the North American market can mostly be attributed to the high prevalence of technologically advanced medical framework, sophisticated insurance & co-payment system & high R&D investment by governments and private funding organizations for the development of POC MDx tests are major factors responsible for the regions dominant market position. Availability of clinical evidence for the safety and efficacy of point of care molecular diagnostics procedures, transmuting technology and innovation.

Asia Pacific market is expected to grow at the fastest rate during the forecast period owing to the increasing demand for POC test. Many minuscule players are looking forward to investment in the Asia Pacific market due to sizable patient pool and incremental utilization of global adhesion barrier market devices.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/10995/

The key players in the Point of Care Molecular Diagnostics Device Market include Roche Diagnostics (Switzerland), Biomerieux (France), Danaher (US), Abbott Laboratories (US), Quidel (US) and Meridian Bioscience (US).

The years that have been considered for the study are:

Base year 2017 Estimated year 2018 Forecast period 2018 to 2026

Target Audience: POC Molecular Diagnostics Manufacturers Physicians Research Institutes Diagnostics Suppliers Market Research and Consulting Firms Regulatory Bodies Venture CapitalistsPoint of Care Molecular Diagnostics Device Market- Key Segment:

Point of Care Molecular Diagnostics Device Market, By Product & Service:

o Assays & Kitso Instruments/Analyserso Services & SoftwarePoint of Care Molecular Diagnostics Device Market, By Application:

o Respiratory diseaseso STDso HAIso Oncologyo HepatitisPoint of Care Molecular Diagnostics Device Market, By Technology:

o RT-PCRo INAATo Others Technologies Point of Care Molecular Diagnostics Device Market, By End User:

o Physician Officeso Hospital Emergency Departments & Intensive Care Unitso Research Instituteso Other End User

Company Profiles:

Abacus Diagnostica Advanced Liquid Logic (Illumina) Ahram Biosystems Akonni Biosystems Alere (Abbott) Amplino Analytik Jena Aquila Diagnostic Systems Atlas Genetics Axxin Becton, Dickinson & Co. (BD) Biocartis Biomeme bioMrieux Canon BioMedical Cepheid Coris BioConcept Coyote Bioscience Curetis DestiNA Genomics Diagnostics For All Diagnostics for the Real World DiaSorin DiAssess DNA Electronics DxNAPoint of Care Molecular Diagnostics Device Market, By Region

North America U.S Canada

Europe Germany France UK Italy Spain Russia Rest of Europe

Asia Pacific Japan China India South Korea Australia Rest of Asia Pacific

Rest of the World (ROW): Middle-East Africa Latin America

MAJOR TOC OF THE REPORT

Chapter One: Point of Care Molecular Diagnostics Device Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Point of Care Molecular Diagnostics Device Market Competition, by Players

Chapter Four: Global Point of Care Molecular Diagnostics Device Market Size by Regions

Chapter Five: North America Point of Care Molecular Diagnostics Device Revenue by Countries

Chapter Six: Europe Point of Care Molecular Diagnostics Device Revenue by Countries

Chapter Seven: Asia-Pacific Point of Care Molecular Diagnostics Device Revenue by Countries

Chapter Eight: South America Point of Care Molecular Diagnostics Device Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Point of Care Molecular Diagnostics Device by Countries

Chapter Ten: Global Point of Care Molecular Diagnostics Device Market Segment by Type

Chapter Eleven: Global Point of Care Molecular Diagnostics Device Market Segment by Application

Chapter Twelve: Global Point of Care Molecular Diagnostics Device Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Point of Care Molecular Diagnostics Device Market Report at:https://www.maximizemarketresearch.com/market-report/point-of-care-molecular-diagnostics-device-market/10995/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Connect With us at LinkedInLinkedIn

Connect with us at FacebookFacebook

Contact With Us at TwitterTwitter

See more here:
Point of Care Molecular Diagnostics Device Market Industry Analysis and Forecast (2019 to 2026) by... - Azizsalon News

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Hunter Syndrome Treatment market.

Trusted Business Insights presents an updated and Latest Study on Hunter Syndrome Treatment Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Hunter Syndrome Treatment market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Hunter Syndrome Treatment Market Size, Share, Market Research and Industry Forecast Report, 2026 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Hunter Syndrome Treatment Market

The global Hunter syndrome treatment market size was valued at USD 864.9 million in 2018 and is expected to witness attractive growth over the forecast period. Introduction of novel therapies, robust product pipeline, rising government initiatives, and increasing awareness regarding Hunter syndrome and its available therapeutic options are expected to significantly fuel the market growth over the forecast period.Hunter syndrome, also known as mucopolysaccharidosis type II (MPS II), is a rare genetic disorder caused by an iduronate-2-sulfatase enzyme deficiency. Presently, there is no permanent cure for Hunter syndrome. Existing treatment including enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT) focuses on providing symptomatic relief and management of complications associated with the disease progression.

According to the data published by the National Institute of Health (NIH) in 2018, Hunter syndrome affects around 1 in 160,000 males globally. The risk of developing this disease is far less among women because they inherit two X chromosomes and one of them can provide a functioning gene if the other X chromosome is defective. However, in men, there is no other X chromosome to compensate for the defective one.Expected approval of novel therapies in late-phase clinical trials and increasing R&D activities by key players for the development of such novel therapies are anticipated to be two major factors driving the market growth in the near future. For instance, in June 2019, Denali Therapeutics Inc. received FDAs Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation for its pipeline drug candidate DNL310, which is being evaluated for the treatment of the disease.Initiatives undertaken by various organizations for creating awareness regarding the disease diagnosis and its treatment is expected to support market growth over the forecast timeframe. For instance, in May 2018, Shire Plc. in collaboration with the National MPS Society and International MPS Network launched its third #FlyforMPS digital campaign aimed to increase awareness about .Treatment InsightsBased on treatment type, the market is categorized into enzyme replacement therapy (ERT), hematopoietic stem cell transplant (HSCT), and others. In 2018, the ERT segment accounted for the largest market share and is anticipated to hold onto its dominance over the forecast period. This is attributed to improved sales of Shire Plcs ELAPRASE and a potential for worldwide approval of GC Pharmas product called Hunterase.

Shire Plcs Elaprase (idursulfase) is the single major drug used for the treatment of Hunter syndrome, with GC Pharmas Hunterase (idursulfase beta) being approved only in South Korea as of now. These drugs have addressed a significant unmet need. However, the high cost of these drugs is expected to be a major factor hindering their market growth. For instance, Idursulfase (Elaprase) drug costs around USD 3,100 per 6mg/3ml vial.

Regional Insights of Hunter Syndrome Treatment Market

In 2018, North America dominated the market owing to favorable regulations for orphan drug development, rising awareness among people concerning rare diseases, increased funding for research activities, and improved healthcare facilities. Furthermore, the favorable reimbursement policies for expensive drugs such as ELAPRASE in the U.S. have supported its adoption and fueled the regional growth.Asia Pacific region is projected to exhibit a lucrative growth rate over the forecast period. Japan, China, and India are expected to emerge as potential countries for growth, owing to their high unmet needs in the market. Major players are focused on gaining approval for their novel therapies and are penetrating these markets to attain a major share. For instance, in July 2019, CANBridge Pharmaceuticals Inc. filed a New Drug Application (NDA) with the National Medical Products Administration (NMPA) for its novel treatment drug called Hunterase in China. Hunterase (idursulfase beta) is a patented therapy of GC Pharma indicated for the treatment of Hunter syndrome.

Market Share Insights of Hunter Syndrome Treatment Market

Some of the key players in the market comprise Shire Plc. (Takeda Pharmaceutical Company); GC Pharma; JCR Pharmaceuticals Co Ltd.; RegenxBio Inc.; Sangamo Therapeutics, Inc.; ArmaGen Inc; Inventiva S.A.; Denali Therapeutics Inc.; Bioasis Technologies Inc.; and Esteve.Currently, Shire Plc. (acquired by Takeda Pharmaceutical Company Limited in April 2019) is a prominent market player, with strong sales of its drug ELAPRASE, indicated for the treatment of Hunter syndrome. However, Shire plc is expected to face stiff competition from Green Cross (GC) Pharma over the forecast period. GC Pharma is emerging as a global player in the Hunter syndrome treatment market with its orphan drug, Hunterase.GC Pharma is undertaking inorganic growth strategies such as partnerships and collaborations for the commercialization and geographical expansion of Hunterase. For instance, in April 2019, Clinigen Group plc and GC Pharma entered into an exclusive licensing agreement under which Clinigen gained the rights to commercialize Hunterase in Japan.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Hunter Syndrome Treatment Market Research ReportThis report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest trends and opportunities in each of the sub-segments from 2015 to 2026. For the purpose of this study, this market research report has segmented the global Hunter syndrome treatment market report on the basis of treatment and region:

Treatment Outlook (Revenue, USD Million, 2019 2030)

Enzyme Replacement Therapy (ERT)

Hematopoietic Stem Cell Transplant (HSCT)

Others

Quick Read Table of Contents of this Report @ Hunter Syndrome Treatment Market Size, Share, Market Research and Industry Forecast Report, 2026 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Read more:
Hunter Syndrome Treatment Market Analysis Of Global Trends, Demand And Competition 2020-2028 - 3rd Watch News

More than two million people in England still won't be able to see friends and family when lockdown rules are eased this weekend.

Rules are changing across the UK - with different numbers of people now allowed to meet up England, Wales, Scotland and Northern Ireland.

But for the 2.16million people told to 'shield' because they are clinically vulnerable, the rules won't change for some time.

George Eustice has warned that those shielding from coronavirus may have to continue to do so for several more months.

Asked about ways to make life easier for those who are shielding, the Environment Secretary told LBC: Well it is something that we are looking at because we completely recognise that those who are shielded and clinically vulnerable who have been told to isolate and not to see friends and family at all, that is going to start taking its toll on them and we want to be able to find ways to be able to do that.

But it is very, very difficult because they are clinically vulnerable and nobody obviously wants to visit family in that group and find that theyve given them the virus.

So we dont have answers yet, thats why they have to remain shielded for the time being, possibly for several more months.

He added that it is a difficult situation with that shielded cohort.

According to the NHS, if you have been identified as needing shielding - if you are at high risk of developing complications - you will have received a letter from your GP, hospital or (if identified nationally) from the national helpline.

Where the NHS holds a mobile number it will have also sent you a series of SMS text messages. These will come from either 07307 810357 or UK_Gov. If you are unclear why you have received a letter, contact your GP or hospital consultant.

You should register yourself on the gov.uk website if you need extra help and support. If you do not register on the website, then you will be contacted by the shielding helpline to confirm that you do not need support.

The call will be made from 0333 3050466. It is not a live telephone line, but if you call it you will get the recorded message: You were called today by the Shielding Helpline, sorry that we missed you, there is no need to call us back as we will try again soon. Thank you, goodbye.

Patients are at moderate risk of developing complications from coronavirus (COVID-19) where:

This includes the following patient groups:

Here is the original post:
Millions of people won't be able to see family for months says minister - MyLondon

My wife and I can both roll our tongues but our son can't. I'm worried about his paternity (Photo: Shutterstock)

I am a 36-year-old woman and have no children, but I am planning on having some in a few years. Is it true that with advancing age I increase my chances of getting a child with Downs syndrome or cerebral palsy?

ALSO READ: Ask the doctor: Covid-19 in children: What do we know?

Yes, these conditions have been associated with problematic pregnancies and abnormal foetal development. After age 35, older eggs tend to have abnormal cell division where the chromosomes may fail to separate in the correct way, leading to an excess number of expected chromosomes.

For example, in Downs syndrome, the foetus has an extra chromosome resulting in what is referred to as trisomy. Cerebral palsy is associated with complications of advanced parental age, especially the mothers. These may include miscarriages, multiple births, high blood pressure, gestational diabetes, and genetic mutations that impact brain development. Studies have also suggested that an older couple is more likely to use infertility procedures that can increase the risk of multiples and other risk factors.

I discovered that my fiances sister has albinism. How likely is it that any of our future children develops the condition?

There is a 50 percent chance your fiance is a carrier for the albinism gene. If this holds true, then there is a 25 percent chance that your future children may develop this condition.

My wife can roll her tongue (the rolling tongue gene). So can I. But our son, now 4, cant. I am worried about my childs paternity but dont want to stir the marriage yet. Do you think I should be worried or is there a genetic explanation?

There should be no cause to worry. More recent studies disputed the misleading assumption that leads to the conclusion that is worrying you. There was a study on identical twins who differed in their tongue-rolling trait, suggesting that the trait was not entirely under genomic influence as identical twins have the same genetic makeup.

I hope to get a child through a sperm bank. Do you think my request for physical characteristics of the sperm donor will help towards getting desirable traits in my future child?

ALSO READ: Ask the doctor: Is penile enlargement surgery considered plastic surgery? Does it work?

Yes, most physical characteristics are easily inherited from parents to their offspring. However, this could be a mixture of traits from both the donor and the recipient.

How far is the world from genetically engineering desirable traits into people and consequently having designer babies?

It is already happening on a smaller scale for certain traits, for example women or men going to sperm banks look for super straights in their donors for IVF procedures.

The world is also moving towards precision medicine, or what is commonly known as personalised medicine where everyone has their medicine tailor-made to suit their genes and condition based on their genetic fingerprint.

With technologies such as CRISPR/Cas9 gene editing, the future of designer babies is possible although ethical considerations in human cloning restrict such practices and may fail to promote advancements in these technologies.

Can I influence my childrens personalities or are they predetermined before birth?

To some extent yes, but personality is influenced by various factors. One component may come from the genes and the other from environmental interactions. For example, exposure to different life circumstances greatly influences ones personality.

ALSO READ: Why its better to have children before your 40s

My four-year-old twins are very different. My son has a real mean streak. Hes always been like that. His sister is kind. I have been responsible for their upbringing so far. Are character traits in the genes?

The difference could be in their genetic makeup. As we know, we inherit half of our genes from each parent and different personality traits could arise from this. In addition, the contrast in their personality could emanate from their daily interactions with the external world, such as from observations.

For More of This Stories Subscribe to the Standard Epaper to get a copy of Eve Woman in the Standard

You also have not told us if you treat the children differently whereby in most cases girls are treated kindly with lots of pampering, which is thus reflected in their behaviour. Boys who are often groomed to harden up to face the real world like men and turn out as brave warriors.

As a geneticist, do you think psychopaths are born or made?

I think it is a mixed bag of fortunes here. Psychopaths could result from nature and nurture. Several studies have pointed to the existence of genetic abnormalities in psychopaths, whereas other cases have risen purely from their upbringing. For example, we have had cases of sociopathic behaviour arising after traumatic experiences and drug addiction.Couples can undergo genetic testing to determine if they have any conditions their children can inherit (Photo: Shutterstock)

I have read a bit about genetic testing for couples, and I am considering it before we start a family. My question is, if they find something worrying (my sister died of sickle cell anaemia) can it be prevented because we know beforehand?

It may not be prevented in its entirety, but may help in early management of the outcome. It may also help in decision making whether to proceed and have children in the full knowledge that they may develop an inherited condition from parents. For your case, you could be a carrier for sickle cell disease and this prepares you to seek genetic therapy such as stem cell transplants to correct the abnormal red (sickle) cells.

I did the BRCA gene test and I have the mutated gene. What are the chances I could get ovarian or breast cancer?

A mutated BRCA gene is only an indicator of higher risk of developing either ovarian or breast cancer. It does not mean that you already have the cancer. It helps you prepare to seek and make a plan for testing and monitoring of signs of the development of these cancers so that preventative or management measures can be instituted. This may help in following a lifestyle that can reduce the chances of accelerating the development of the disease.

Is there a genetic explanation as to why children, especially firstborns, look like their fathers?

Well, it is not always the case. Physical characteristics of the offspring sometimes might be a mixture of both the mothers and fathers characteristics. There are, however, extremes where a child may look like a copy of either parent. A child is a result of the union of genes of a mother and father, and the strength of expression of these genes may differ.

There is conflicting information out there about genetically modified foods. What are the facts and fiction on this?

Genetically modified foods refer to food items whose source material production, be it plant or animal, involves intentional mixing (manipulation) of genetic material not naturally found in the pure/natural breed.

The fuss brought about by anti-GMO campaigners has been related, in my opinion, to a lack of information. The genes being included have their function known from a science point of view. However, genes may interact and the results may not be known fully. How a gene will behave in the new organism is assumed to be what is known, but it does not rule out undesired effects. However, before a gene is used in GMO, experimental tests are usually performed to understand different scenarios under which it may elicit undesired effects.

Dr Fredrick Nindo, a geneticist, is a visiting post-doctoral research fellow at the Mediterranean Infection Institute for Research in Cancer and Ageing, France.

Do not miss out on the latest news. Join the Eve Digital Telegram channel HERE.

Excerpt from:
Ask the doctor: Is there a chance I am not my sons father? - The Standard

Other Applications

In addition, the report categorizes product type and end uses as dynamic market segments that directly impact the growth potential and roadmap of the target market. The report highlights the core developments that are common to all regional hubs and their subsequent impact on the holistic growth path of the Personalized Medicine market worldwide. Other valuable aspects of the report are the market development history, various marketing channels, supplier analysis, potential buyers and the analysis of the markets industrial chain.

Ask For Discounts @ https://www.marketresearchintellect.com/ask-for-discount/?rid=254994&utm_source=WCS&utm_medium=888

Table of Content

1 Introduction of Personalized Medicine Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Personalized Medicine Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Personalized Medicine Market, By Deployment Model

5.1 Overview

6 Personalized Medicine Market, By Solution

6.1 Overview

7 Personalized Medicine Market, By Vertical

7.1 Overview

8 Personalized Medicine Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Personalized Medicine Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=254994&utm_source=WCS&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Personalized Medicine Market Size, Personalized Medicine Market Trends, Personalized Medicine Market Growth, Personalized Medicine Market Forecast, Personalized Medicine Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Originally posted here:
Personalized Medicine Market Research Report 2020: Key Players, Applications, Drivers, Trends and Forecast to 2026 - WaterCloud News

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Precision Medicine market.

Trusted Business Insights presents an updated and Latest Study on Precision Medicine Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Precision Medicine market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Precision Medicine Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Abstract, Snapshot, Market Analysis & Market Definition: Precision Medicine MarketIndustry / Sector Trends

Precision Medicine Market size was valued at USD 52.6 billion in 2018 and is expected to witness 10.5% CAGR from 2019 to 2025.

U.S.Market Segmentation, Outlook & Regional Insights: Precision Medicine Market

Precision Medicine Market, By Technology, 2018 & 2025 (USD Million)

Growing demand and advancements in cancer biology will drive personalized medicine market during the forecast period. Accessibility to large-scale human genome database including next-generation sequencing (NGS) and computational tools foster industry growth. Development of innovative genetic technologies examines the functional effect of genetic makeup that leads in developing cancer, thus, should propel huge demand for cancer biology. Several such tools are widely used to study the mechanism of DNA repair, epigenetic changes related to cancer and gene regulation in cancerous cells that offer opportunities for cancer biology in personalized medicine.

Moreover, improving efficiencies within the health care system will serve to be positive impact rendering factor personalized treatment business growth. Benefits offered by personalized medicines and treatment includes target treatment for patient, optimal dosing, focus on prevention and earlier intervention as well as preventing adverse events. Thus, above mentioned features will foster the demand for personalized medication market growth. However, high cost associated with precision medicine may impede industry growth over the forecast period.

Precision Medicine Market, By Technology

Drug discovery segment held over 21% revenue share in 2018 and is projected to grow significantly by 2025. Focus of business players on developing technologically advanced drugs enabling superior treatment for several life-threatening diseases will create segmental growth opportunities. Bio-pharmaceutical companies utilize bioinformatics software to introduce customized novel drugs that should augment the segmental growth.

Gene sequencing segment is anticipated to show exponential CAGR of around 11% over the coming years. Benefits offered by gene sequencing technique such as relevant information about patients genome and biological research ensures quick drug discovery process that should boost segmental growth.

Precision Medicine Market, By Application

Immunology segment accounted for over USD 9.5 billion in 2018 and is estimated to witness considerable growth trend during the analysis period. Growing demand for bioinformatics and big data analytics to segregate human genome data obtained from immunological processes favors segmental growth.

Oncology segment held significant revenue share in 2018 and is assessed to show more than 10.5% CAGR during the forecast period. Segment growth is attributable to increasing prevalence of cancer cases resulting in development of innovative drugs with specific drug formulations in precision medicine.

Germany Precision Medicine Market Size, By Application, 2018 (USD Million)

Precision Medicine Market, By End-use

Healthcare IT companies segment held more than 27% revenue share in 2018 and will show lucrative growth over coming years. Increasing demand for developing technologically advanced tools for rapid integration, storage, and analysis of patient data should augment the business growth.

Diagnostic companies segment was valued around USD 9.5 billion in 2018. Such companies provide solutions that bridges the gap between clinical needs of patients and technology. Various benefits such as high quality of the medical diagnostic devices enabling precise patient management will foster industry growth.

Precision Medicine Market, By Region

North America precision medicine market is predictable to show around 9% CAGR over the analysis period. Rising prevalence of respiratory and oncology diseases as a result of lifestyle changes is the key factor driving demand for market. Rising healthcare expenditure coupled with presence of major industry players in North America will spur the business growth.

Asia Pacific precision medicine industry was valued more than USD 11 billion revenue in 2018. Regional growth can be attributed to technological advances in sequencing technology. Moreover, presence of large patient pool in Asia Pacific along with growing investments in R&D activities will accelerate personalized medication business growth.

MEA Precision Medicine Market Size, By Country, 2025 (USD Million)

Key Players, Recent Developments & Sector Viewpoints: Precision Medicine Market

Few of the prominent industry players operating in precision medicine industry include Biocrates Life Sciences, Tepnel Pharma Services, Qiagen, Menarini Silicon Biosystems, Novartis, NanoString Technologies, Pfizer, Eagle Genomics, Quest Diagnostics, Roche, Intomics, and Teva Pharmaceutical. The business players implement several strategies including acquisitions, partnerships and innovative product enhancement to capitalize on market growth opportunities.

Recent industry developments:

In October 2018, Eagle Genomics partnered with Microsoft Genomics to tackle computational challenges of genomics era. This partnership aimed to inculcate scale and power of cloud to precision medicine, across the production of fundamental research and core services.

In January 2018, Syapse collaborated with Roche in order to advance precision medicine in oncology. Also, this partnership focuses on clinical delivery and product development for introducing precision medicine to more patients.

Precision Medicine Industry Viewpoint

History of precision medicine can be tracked back in 1950s when Watson and Crick discovered the structure of the DNA as double-helix. Efforts to supplement the DNA structure, researchers cracked the genetic code in early 1960s. Additionally, introduction of the first DNA sequencing technology was developed in 1970s where researchers discovered first enzyme linked to individual variation in response to dosing. In early 1980s Polymerase Chain Reaction (PCR) was first discovered allowing for fast amplification of DNA sequences. These advances continued in 1990s where human genome project was launched along with FDA approval for first personalized medicine with a companion diagnostic, for the treatment of HER2 positive breast cancer. Such form of advancements continued in 2000s where first targeted therapies for lung cancer, leukemia, melanoma, cystic fibrosis, HIV, and other diseases accelerated tremendous growth opportunities for precision medicine. Moreover, increasing demand for personalized medication for secured patient management will drive industry growth during the forthcoming years

Key Insights Covered: Exhaustive Precision Medicine Market1. Market size (sales, revenue and growth rate) of Precision Medicine industry.2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Precision Medicine industry.3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Precision Medicine industry.4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Precision Medicine industry.

Research Methodology: Precision Medicine Market

Quick Read Table of Contents of this Report @ Precision Medicine Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Visit link:
Precision Medicine Market Overview By Growing Demands, Trends And Business Opportunities 2020 To 2027 - Cole of Duty

Abraham Maslow said in 1966, I suppose it is tempting, if the only tool you have is a hammer, to treat everything as if it were a nail. This mentality known as the Law of the Instrument indicates that people tend to rely on the tool with which they are most familiar.

In a healthcare setting, that can translate into only using traditionally trained medical professionals to handle every situation, but in reality, some issues require a collaborative approach that includes other skills and experience. This is particularly relevant when it comes to addressing social determinants of health (SDoH).

Social determinants of health can include many things: food, housing and transportation insecurities; lifestyles, locations and surroundings; social isolation; and other factors that prevent people from achieving and maintaining good health. Non-clinical influences like these can drive up to 80% of clinical outcomes, affecting an individuals ability to be healthy.

In other words, it takes more than the latest treatments to keep people healthy. Much work is being done to address social determinants at the public health level, but these factors must also be addressed at the patient level. The paradox about population health is that its all about individuals and using a collaborative approach can be the key to success.

Why the Collaborative Approach WorksStudies indicate that patients who perceive their providers as more empathetic tend to get better more quickly, and experience less severe symptoms. Yet providers sometimes lack the capacity to treat patients holistically, or the data and insights to understand why a patient isnt taking their medicine, even though insights into social barriers can guide how providers should interact with patients.

Educating a patient is helpful, but typically not effective at changing behavior, especially when social factors are at work. Additionally, people trained in the medical field are not also trained and resourced to deliver interventions involving social factors.

This is where an interdisciplinary team approach can help to improve population health by addressing social determinants at the individual level. The best approach to care involves a team that includes a range of medical professionals, social workers, behavioral health specialists and community health coaches, all working together to formulate and deliver a comprehensive support plan tailored to each patients priorities and needs.

Instead of telling patients what to do, local care teams can work with patients to understand their barriers, such as lack of transportation or housing insecurity, and tap local resources to reduce or remove them. By simply asking the right questions, community health coaches can get much more tactical and concrete about supporting the individual and tailoring treatment support plans.

Additionally, these coaches often live in the same community and understand the context of peoples lives, which improves communication and creates trust. In fact, Medicaid members who receive community-based services are less likely to be admitted to the ER or as an inpatient in a hospital. During one-on-one interactions, community health specialists are well-positioned to understand the social roadblocks to access care and adhering to treatment plans.

A collaborative team is ideally suited to assess the social and environmental factors impacting a persons health, identify barriers of care, and create a personalized support plan that may include services such as behavioral health support, patient advocacy, and remote monitoring technology to remove those barriers and improve care plan adherence.

The Four Components of SuccessA successful strategy to address social determinants of health comprises four components:

Analytics: In any population health intervention, the team needs to identify through stratification who is at the greatest risk, to properly titrate the resource intensiveness of an intervention. If you try to intervene equally with everyone, your efforts (and funds) will be spread too wide and too thinly.

Using analytics on the front end can ensure that the people with the highest risk are receiving more intensive treatments. Healthcare teams can look to existing data sets like consumer marketing data, which often is a treasure trove of information on factors that affect health such as transportation, housing issues and financial stress. For example, data can reveal if an individual lives alone, owns a car, or lives near public transportation all factors that impact a persons ability to follow through with their care plan. These insights can be integrated with data on medical risk and cost of care before the amalgamated data set is stratified.

A multidisciplinary support team: As stated, for social determinants to be addressed on an individual level requires an integrated team of both clinical and social support experts and community-based coaches are essential contributors.

The right toolbox from which to draw: There are existing toolboxes of interventions for housing, food insecurity and stress management, and the care team should recognize what needs to be addressed and draw from existing strategies to address healthcare at the social level. Interventions that mitigate the social stressors impacting an individual around the clock provide the greatest health benefits.

Respect for the individuals priorities: A population health team must have the flexibility to prioritize what the individual sees as the greatest issue. For example, a homeless individual might have a substance use disorder (SUD). Typically, people with SUD cannot get into housing until they are in recovery; however, if the individual is not ready to work on their recovery, but does see stable housing as a stepping stone toward recovery, that should be respected so work first on what theyre ready to work on.

A Better Approach to Addressing Population HealthWhile the use of multidisciplinary teams can involve significant changes to work practices and organizational arrangements, providing community-based resources is essential to addressing social barriers that affect health and wellness.

By understanding the social factors that can impact patient wellness, and employing a collaborative approach to individual care, payers, providers and patients will reap the benefits of more successful outcomes improving population health overall.

Photo: marchmeena29, Getty Images

See the original post here:
The paradox of population health: Focus on personalized support for the greatest impact - MedCity News

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will expand its robust menu of ready-to-use Simoa kits to include tau phosphorylated at threonine 181 (p-tau181), a highly specific biomarker for the study of Alzheimers disease pathology, in cerebral spinal fluid (CSF), serum and plasma. A growing body of research, including work published recently in The Lancet Neurology, suggests that the biomarker could prove critical to predicting Alzheimers disease progression and differentiating the disease from other neurodegenerative disorders. Moreover, an ultra-sensitive, blood p-tau181 assay may hold the key to advancing preventative care for the disease in clinics and via homecare sampling through a simple, cost-effective blood-based screening that can deliver an early, objective diagnosis. These findings and details on how researchers can gain early access to Quanterix new commercial assay through the Simoa Accelerator Laboratory, will be discussed during an upcoming Powering Precision Health (PPH) Think Tank Webinar taking place at 10 a.m., EDT on June 3, 2020.

Biomarkers continue to play an invaluable role in understanding how neurological diseases manifest, progress and respond to treatment, said Kevin Hrusovsky, Chairman, Chief Executive Officer and President, Quanterix. Building on years of innovation and a proven track record for successfully commercializing ultra-sensitive assays that disrupt markets and drive innovative breakthroughs forward, our p-tau181 version 2 assay kit offers researchers unrivaled visibility and specificity into this revolutionary marker in serum and plasma. The exquisite sensitivity of Simoa uniquely positions us to deliver on the promise of p-tau181 to pave new pathways in Alzheimers disease exploration, just as our neurofilament light chain (Nf-L) assay has transformed research for other neurological diseases. In particular, the impact of a high-definition, blood-based Simoa assay that rivals traditional CSF or PET scans could be revolutionary, with material potential for home sampling to enable early detection and development and approval of drug therapies desperately needed to improve outcomes for the millions of people living with Alzheimers disease today. This biomarker advance fits perfectly in our vision to transform reactive sick care' into proactive asymptomatic precision healthcare.

While deaths associated with other pervasive diseases such as heart disease have declined between 2000 and 2018, Alzheimers disease-related deaths have increased by 146 percent, according to the Alzheimers Association. Importantly, there is no objective test to diagnose the disorder, leading many physicians to rely solely on subjective cognitive assessments. As a result, many patients are not diagnosed until late in the diseases progression, after symptoms of cognitive decline, such as memory loss, begin to present. Even then, the disease can often be misdiagnosed for another neurodegenerative condition, such as frontotemporal dementia (FTD).

For years, researchers have studied the utility of biomarkers for understanding, detecting and monitoring Alzheimers disease. These efforts have been accelerated in large part by the PPH network, which has grown into a global epicenter for biomarker-enabled innovations to not only detect and treat, but ultimately, prevent disease. Resulting studies demonstrate the vast utility of proteins such as total tau and Nf-L. Researchers, doctors and pharmaceutical companies are now harnessing these biomarkers to see the disease earlier, monitor its progression and inform clinical decision making more effectively, and assess the viability of experimental therapies. Quanterix ultra-sensitive immunoassay technology, Simoa, which empowers single- and multi-plex detection of key biomarkers with 1000 times greater sensitivity than competing enzyme-linked immunosorbent assay (ELISA) solutions, is the driving technology behind much of this research. Among the most notable is a 2019 Nature Medicine paper that used Simoa to see signs of Alzheimers disease 16 years before symptoms through the high-definition detection of Nf-L. The technology has powered hundreds of similarly peer-reviewed journals over the years that demonstrate the potential for blood-based detection of the disease with equal or greater sensitivity as compared to CSF or PET biomarkers. Collectively, these studies create an influential body of research that advances the preventative care paradigm envisioned by PPH at its inception by supporting the utility of a non-invasive and easily administered blood test to detect Alzheimers disease before symptoms.

Today, emerging research suggests that p-tau181 could hold even greater diagnostic promise for Alzheimers disease, as it has proven capable of differentiating the condition from other forms of dementia with greater specificity than total tau. Leaders in the field of neurodegenerative disease research, such as the authors of The Lancet Neurology paper Professors Henrik Zetterberg, MD, PhD, and Kaj Blennow, MD, PhD, of the University of Gothenburg, believe blood p-tau181 has the potential to revolutionize Alzheimers disease research and patient care in much the same way that serum-based Nf-L has for multiple sclerosis (MS).These concepts further progress PPHs mission and vision to harness biomarkers for true precision health, with myriad implications that include improving understanding of the condition, enabling earlier diagnosis and intervention, informing more accurate long-term care, identifying clinical trial candidates earlier in the disease cascade and, subsequently, accelerating promising new therapies to market.

The latest installment of the PPH Think Tank series of webinars, entitled Novel p-tau181 Blood Immunoassay and the Future of Alzheimers Disease Research, will explore the vast opportunities associated with p-tau181 to revolutionize the way we approach disease and administer care. Specifically, the discussion will detail how an innovative immunoassay to measure p-tau181 in blood could accelerate efforts to establish a clinically relevant routine Alzheimers disease diagnostic test, and the potential high-definition detection via small volume blood samples creates for homecare precision health. Hrusovsky, together with Professors Zetterberg and Blennow, will break down the findings from the recent paper in The Lancet Neurology and examine how Simoa is powering exploration into uncharted territory as it pertains to Alzheimers disease detection, monitoring, treatment and prevention.

Were on the cusp of what could be an incredible new era for Alzheimers patients and those with a genetic predisposition to the disease, said Zetterberg. The ability to see dementia asymptomatically and moreover conclusively distinguish it as Alzheimers disease-induced could forever change the face of this condition. P-tau181 shows immense promise in this regard, which is augmented considerably when harnessed by a leader in detection like Quanterix.

Early findings from our work with p-tau181 are very encouraging, said Blennow. The biomarker is proving to be an exceptional new tool in our arsenal against Alzheimers disease. While CSF p-tau181 has been recognized as a highly valuable biomarker in Alzheimers disease pathology, the greater clinical benefit will come from our ability to effectively harness the marker in blood. The unprecedented specificity of p-tau181 paired with a highly sensitive technology like Simoa promises to broaden our knowledge of this devastating disease considerably, with monumental implications for patients and caregivers.

To register for the webinar, click here.

To learn more about how you can take advantage of our early access program for p-tau181 through the Accelerator Lab or pre-order your commercial kits, visit https://www.quanterix.com.

For more about Quanterix Simoa technology, visit https://www.quanterix.com/Simoa-bead-technology.

About Quanterix

Quanterix is a company thats digitizing biomarker analysis with the goal of advancing the science of precision health. The companys digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.

About Powering Precision Health

Powering Precision Health is the world's first independent, non-profit organization dedicated to bringing the world's leading physicians, scientists, innovators, investors and patient advocates together to unveil their latest research on new biomarkers that are revolutionizing precision health. Founded by Kevin Hrusovsky, a widely acclaimed thought leader and visionary in life sciences and personalized medicine, Powering Precision Health is a movement that represents the intersection of new technological capabilities with the latest medical research. Its rooted in the science of precision medicine, which shows personalized treatments to be an increasingly more effective way to maximize drug efficacy and minimize toxicity. In addition to the impact environmental and lifestyle factors can have on minimizing disease triggers, precision health marks an evolution in the way we approach disease and aims to inspire a full healthcare transformation, from philosophy to approach to outcome. In an industry often plagued by skepticism and marred by false promises, PPH puts science first and brings together stakeholders that span from fundamental research to clinical practice, investors, policy makers, patient advocacy groups, and anyone who embraces the vision of Powering Precision Health. Featuring a distinguished keynote lineup of dignitaries, the Summit unveils groundbreaking approaches to prevention, early diagnosis, and next-generation treatments. Powering Precision Health is supported thanks to the generous contributions of sponsors from a wide range of companies and organizations committed to advancing precision health.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

See more here:
Quanterix Expands Menu of Ultra-Sensitive Neurology Assays with Simoa P-Tau181 V2 Kit for Improved Detection and Study of Alzheimer's Disease -...

New Jersey, United States, The Personalized Medicine Market report examines the market situation and prospects and represents the size of the Personalized Medicine market (value and volume) and the share by company, type, application and region. The general trends and opportunities of Personalized Medicine are also taken into account when examining the Personalized Medicine industry. Personalized Medicine The market report focuses on the following section: Analysis of the Personalized Medicine industry by transfer into different segments; the main types of products that fall within the scope of the report.

This Personalized Medicine market report is a complete analysis of the Personalized Medicine market based on an in-depth primary and secondary analysis. The scope of the Personalized Medicine market report includes global and regional sales, product consumption in terms of volume and value. The Personalized Medicine market report contains an estimate of revenue, CAGR and total revenue. The knowledge gathered in world trade Personalized Medicine is presented in figures, tables, pie charts and graphics.

Get | Research Sample Copy By Using Corporate Mail ID @https://www.verifiedmarketresearch.com/download-sample/?rid=7106&utm_source=COD&utm_medium=007

Top 10 Companies in the Global Personalized Medicine Market Research Report:

Global Personalized Medicine Market: Drivers and Restrains

The research report included analysis of various factors that increase market growth. These are trends, restrictions and drivers that change the market positively or negatively. This section also contains information on various segments and applications that may affect the market in the future. Detailed information is based on current trends and historical milestones. This section also includes an analysis of sales volume on the Personalized Medicine market and for each type from 2015 to 2026. This section mentions sales volume by region from 2015 to 2026. The price analysis is included in the report Type of year 2015 to 2026, manufacturer from 2015 to 2020, region from 2015 to 2020 and total price from 2015 to 2026.

An in-depth assessment of the restrictions contained in the report describes the contrast to the drivers and leaves room for strategic planning. The factors that overshadow the growth of the market are essential as they can be understood to design different phrases to take advantage of the lucrative opportunities that the growing Personalized Medicine market offers. In addition, information on the opinions of market experts was used to better understand the market.

Global Personalized Medicine Market: Segment Analysis

The research report contains certain segments such as application and product type. Each type provides revenue information for the 2015-2026 forecast period. The application segment also provides volume revenue and revenue for the 2015-2026 forecast period. Understanding the segments identifies the importance of the various factors that support Personalized Medicine market growth.

Global Personalized Medicine Market: Regional Analysis

The research report includes a detailed study of the regions of North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. The Personalized Medicine report was compiled after various factors determining regional growth, such as the economic, environmental, social, technological and political status of the region concerned, were observed and examined. Analysts examined sales, sales, and manufacturer data for each region. This section analyzes sales and volume by region for the forecast period from 2015 to 2026. These analyzes help the reader understand the potential value of investments in a particular region.

Global Personalized Medicine Market: Competitive Landscape

This section of the report lists various major manufacturers in the market. It helps the reader understand the strategies and collaborations that players focus on to fight competition in the market. The full report provides a significant microscopic overview of the Personalized Medicine market. Readers can identify manufacturers footprints by knowing manufacturers global earnings, manufacturers world market prices, and manufacturers sales for the 2015-2019 forecast period.

Ask For Discounts, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7106&utm_source=COD&utm_medium=007

Table of Content

1 Introduction of Personalized Medicine Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Personalized Medicine Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Personalized Medicine Market, By Deployment Model

5.1 Overview

6 Personalized Medicine Market, By Solution

6.1 Overview

7 Personalized Medicine Market, By Vertical

7.1 Overview

8 Personalized Medicine Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Personalized Medicine Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @https://www.verifiedmarketresearch.com/product/global-personalized-medicine-market-size-and-forecast-to-2026/?utm_source=COD&utm_medium=007

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defence, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

See the article here:
Personalized Medicine Market Growth Analysis by Size, Top Companies, Supply Demand, Trends, Demand, Overview and Forecast to 2026 - Cole of Duty

SALT LAKE CITY, May 29, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, today announced the presentation of two new studies at the 2020 American Society of Clinical Oncology (ASCO) annual meeting demonstrating the ability of Myriads riskScore test to provide personalized breast cancer risk information that allows patients and physicians to make better informed clinical treatment decisions.

We are excited to further demonstrate Myriads commitment to providing the best possible risk assessment tools to patients through innovation, said Nicole Lambert, president of Myriad Oncology, Myriad Womens Health and Myriad International. The validation data we are presenting at ASCO this year will support a broader launch of riskScore to even more women in the coming year with more personalized information and the unique ability to modify carrier risk through a clinically validated tool.

Summaries of the studies are below. Follow Myriad on Twitter via @myriadgenetics and keep up to date with ASCO meeting news and updates by using the #ASCO20 hashtag.

riskScore Presentations at 2020 ASCO:

Title:Comprehensive breast cancer (BC) risk assessment for CHEK2 carriers incorporating a polygenic risk score (PRS) and the Tyrer-Cuzick (TC) modelPresenter:Mark E. Robson, MD, Memorial Sloan Kettering Cancer CenterLocation:https://meetinglibrary.asco.org/record/187438/abstract

In this study, 358,471 women with hereditary cancer risk who were tested with a multigene panel were assessed to find 4,331 women who were carriers of deleterious CHEK2 mutations. These patients were used to develop a mathematical model to assess risk status using family history information and Myriads riskScore test. This model was then validated in an independent cohort of 459 women. In CHEK2 pathogenic variant carriers, a significant correlation was detected of CHEK2 status with family history (FH) (p=4.1 10-17) and of polygenic risk scores with FH among CHEK2 carriers (p=1.7 10-5). Among the patients in the validation cohort, 24.0% of CHEK2 carriers were categorized as low risk (<20%), and 62.6% were categorized as moderate risk (20-50%). For 13.4% of CHEK2 carriers, risk estimation incorporating PRS and TC generated BC risks of greater than 50%, consistent with genes recognized as highly penetrant.

To view Graph 1: Precision Breast Cancer Risk Categorization of CHEK2 Carriers,please visit the following link:https://www.globenewswire.com/NewsRoom/AttachmentNg/1a4a8828-8282-47df-9e4d-b82f11604b2b

Title:Performance of the IBIS/Tyrer-Cuzick (TC) Model by Race/Ethnicity in the Womens Health InitiativePresenter:Allison W. Kurian, M.D., M.Sc, Stanford UniversityLocation:https://meetinglibrary.asco.org/record/185965/abstract

In this study, 91,893 women of differing racial identities with no personal history of breast cancer were followed for a median of 18.9 years to assess incidence of breast cancer. 6,836 new cases of breast cancer were diagnosed among the women. The Tyrer-Cuzick model was used to assess risk of breast cancer and then actual cases of breast cancer were compared to expected cases based upon the Tyrer-Cuzick risk assessment. The study found that the Tyrer-Cuzick model was an accurate predictor of breast cancer risk among various ethnicities except for Hispanic women where it overestimated breast cancer risk (ratio of observed versus expected cases overall was 0.95).

About riskScoreriskScore is a new clinically validated personalized medicine tool that enhances Myriads myRisk Hereditary Cancer test. riskScore helps to further predict a womens lifetime risk of developing breast cancer using clinical risk factors and genetic-markers throughout the genome. The test incorporates data from more than 80 single nucleotide polymorphisms identified through 20 years of genome wide association studies in breast cancer and was validated in our laboratory to predict breast cancer risk in women of European descent. This data is then combined with a best-in-class family and personal history algorithm, the Tyrer-Cuzick model, to provide every patient with individualized breast cancer risk.

About Myriad myRisk Hereditary CancerThe Myriad myRisk Hereditary Cancer test uses an extensive number of sophisticated technologies and proprietary algorithms to evaluate 35 clinically significant genes associated with eight hereditary cancer sites including: breast, colon, ovarian, endometrial, pancreatic, prostate and gastric cancers and melanoma.

Story continues

About Myriad GeneticsMyriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to a broader launch of riskScore to even more women in the coming year with more personalized information and the unique ability to modify carrier risk through a clinically validated tool; and the Companys strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Read this article:
Myriad Presents New Data at ASCO Validating the Ability of riskScore to Provide Personalized Breast Cancer Risk Information to Patients - Yahoo...

3DHEALS 2020

SAN FRANCISCO (PRWEB) May 29, 2020

3DHEALS, LLC is pleased to announce its global virtual summit 3DHEALS 2020, June 5th- June 6th, focusing on healthcare innovations using 3D printing, bioprinting, and related technologies. The event expects 500+ attendees from 20+ countries, and 20 early-stage startups to participate in Pitch3D, a fast-paced pitch event to institutional investors. 3DHEALS 2020 addresses the need for a global cross-disciplinary forum. It will feature more than 70 world-class experts from more than 60 organizations and companies to showcase technological developments, share insights, tackle challenges, and present opportunities for future collaborations. The content-rich two-day multi-track virtual summit allows the attendees to learn practical knowledge from world-class experts, including hands-on application-focused workshops. The organizers have conducted more than 29 speaker interviews, which can also be downloaded as podcasts.

The virtual summit is not just two days of webinars, but a simulated virtual networking experience, where speakers, exhibitors, and attendees can engage through the conference's dedicated mobile app, before, during, and after the meeting. The fee for the conference is 100 USD.

The two-day virtual event offers nineteen sessions. While there is no dedicated COVID-19 panel, many presentations address how 3D printing and bioprinting communities respond to the pandemic.

Highlighted presentations and panels include the following:

In the first keynote presentation, Sam Onukuri, Head and Senior Fellow at Johnson & Johnson 3D Printing, will explain how the world's largest healthcare company is leveraging 3D printing technology to transform the design, manufacturing and delivery ecosystem across Johnson & Johnson's medical device, consumer and pharmaceutical businesses.

In the second keynote presentation, Dr. Alan Dang, an orthopedic spine surgeon and co-founder of PrinterPezz, will share the "behind-the-scenes secrets" of how PrinterPrezz democratizes medical device innovation and helps its customers go from concept to production.

The biofabrication and bioprinting panels collect some of the brightest minds in the world of tissue engineering and biofabrication, tackling 3D printing nearly every organ system from brain tissue, vasculatures, to heart valve. Many speakers are well-known scientists, including professors Stephanie Willerth, Adam Feinberg, Jordan Miller, who are also co-founders behind some of the newest startups in the bioprinting space. More established companies critical to tissue engineering and cell therapy will also join the conversation, including Melanie Mathieu from Prellis Biologics, Jon Rawley from Roosterbio, John O'Neil from Xylyx, Taciana Pereira from Allevi, and Kevin Caldwell from Ossium Health, and Qrquidea Garcia ("Orchid") from JNJ.

A related panel focusing on 3D printing on the International Space Station also deserves much attention from speakers from Techshot, ISS/CASIS, and Allevi (Ricky Solorzano).

The legal and regulatory panel will include the most comprehensive list of legal and regulatory concerns, focusing on healthcare 3D printing applications. The topics include intellectual property/patent issues(Roger Kuan, Haynes and Boone LLP), product liability, FDA pathways, manufacturing standards, and more. Steven Bauer, from FDA CBER, will address concerns related to cell therapy and stem cells.

The early morning Global Perspective sessions are reserved for international speakers to share their unique experiences, needs, and hopes. Both America Makes director John Wilczynski and NAMIC director Dr. Chaw Sing Ho, along with experts from Turkey, India, and Taiwan, will share how 3D printing and bioprinting innovations can thrive in both local and global healthcare environs. The audience will also learn about how different countries are implementing the concept of 3D printing for Point of Care, with experts from UCSF, Stanford, Germany (Kumovis), India (Anatomiz3D), Korea (MEDICALIP), and developing countries. More than ten 3DHEALS community managers will also present city-based healthcare 3D printing innovation ecosystems and share their progress.

As one of the largest sectors in FDA cleared devices, metal and orthopedic 3D printing will permeate throughout the entire conference, from keynotes to dedicated panels focusing on materials, designs (nTopology, ANSYS, MEDICALIP), and end-user applications head to toe (Printerprezz).

As a fast-growing sector, the dental 3D printing panel will feature an unprecedented group of speakers from a combination of academia (University of Michigan, USC, UOP) and industry (Boneeasy, Origin) focusing on critical issues facing the industry both short and long term.

The material science panel will feature speakers from Henkel, Evonik, Origin, and 3Degrees for an in-depth discussion on what roles material manufacturers should play in 3D printed medical devices, investment opportunities, and the latest trends.

The investor panel will feature VCs in the medtech and life science space, including NEA, Intuitive Surgical, Evonik, and more.

The entrepreneur fireside chat session will invite CEOs of Aspect Biosystems and Fluidform to share their perspectives based on their startup journeys.

Go here to see the original:
3DHEALS 2020: Join The Frontier Of Healthcare 3D Printing - PR Web

DUBLIN, May 28, 2020 /PRNewswire/ -- The "Nuclear Medicine Imaging Equipment - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Amid the COVID-19 crisis and the looming economic recession, the Nuclear Medicine Imaging Equipment market worldwide will grow by a projected US$525 Million, during the analysis period, driven by a revised CAGR of 2.9%. Hybrid Positron Emission Tomography (PET) Systems, one of the segments analyzed and sized in this study, is forecast to grow at over 3.5% and reach a market size of US$1.3 Billion by the end of the analysis period. The Hybrid Positron Emission Tomography (PET) Systems market will be reset to a new normal which going forwards in a post COVID-19 era will be continuously redefined and redesigned. Staying on top of trends and accurate analysis is paramount now more than ever to manage uncertainty, change and continuously adapt to new and evolving market conditions.

As part of the new emerging geographic scenario, the United States is forecast to readjust to a 1.8% CAGR. Within Europe, the region worst hit by the pandemic, Germany will add over US$12.2 Million to the region's size over the next 7 to 8 years. In addition, over US$13 Million worth of projected demand in the region will come from Rest of European markets. In Japan, the Hybrid Positron Emission Tomography (PET) Systems segment will reach a market size of US$62.5 Million by the close of the analysis period. Blamed for the pandemic, significant political and economic challenges confront China. Amid the growing push for decoupling and economic distancing, the changing relationship between China and the rest of the world will influence competition and opportunities in the Nuclear Medicine Imaging Equipment market. Against this backdrop and the changing geopolitical, business and consumer sentiments, the world's second largest economy will grow at 5.9% over the next couple of years and add approximately US$176.5 Million in terms of addressable market opportunity.

Continuous monitoring for emerging signs of a possible new world order post-COVID-19 crisis is a must for aspiring businesses and their astute leaders seeking to find success in the now changing Nuclear Medicine Imaging Equipment market landscape.

Competitors identified in this market include, among others:

Key Topics Covered:

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/e8egzt

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Visit link:
World Nuclear Medicine Imaging Equipment Market Analysis, Featuring Digirad Corporation, GE Healthcare, Mediso Medical Imaging Systems and Philips...